Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Journal of the American Academy of Orthopaedic Surgeons

Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

THThien-Huong HuynhBCBryan ClampittCCChloe Chose

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows CAR-T therapy reduces fracture risk in multiple myeloma patients, suggesting clinical benefits.

Key Points

  • CAR-T therapy led to a significant reduction in fracture risk among patients with multiple myeloma.
  • Before CAR-T treatment, 27.8% of patients were classified as at risk for fractures, dropping to 2.5% post-therapy.
  • The primary analysis employed a retrospective cohort study based on PET-CT imaging before and after CAR-T infusion.
  • This study highlights the potential of CAR-T therapy to address both malignancy and associated fracture risks.

Cite This Study

Huynh et al. (2025) studied this question.

synapsesocial.com/papers/68d4232f713b0b5dfea6b3eehttps://doi.org/10.5435/jaaos-d-25-00392
View Full Paper
Ask AI
Bookmark
Share